Evolus completes Phase 2 study evaluating ‘Extra-Strength’ dose of Jeuveau

Evolus announced the completion of its Phase 2 clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau, prabotulinumtoxinA-xvfs, its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics. Presentation of the full dataset will be planned for a medical meeting in Q4 2023. Interim data presented at the 2023 International Master Course on Aging Science, IMCAS, World Congress showed Jeuveau Extra-Strength at 40U units demonstrated 6 months duration across the three metrics presented, including the time it takes for patients to return to their baseline Glabellar Line Scale GLS score after their treatment, time back to baseline for patients with a response of none or mild on the GLS, and the duration of effect of at least a one-point GLS improvement. The adverse events profile across all three arms was similar. The severity rating demonstrated that 88% of the events were mild and 12% were moderate. Importantly, no serious adverse events were reported. “Concluding this Phase 2 clinical study marks another significant milestone for Evolus and our commitment to delivering continued product innovation,” said Rui Avelar, M.D., Chief Medical Officer and Head of Research and Development, Evolus. “We were encouraged by the results of the interim analysis, which took place midway through the study, and now that all the patients have completed the study, we are excited to present the final one-year results, which we believe will demonstrate continued success over time.”